Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2023, titled "(1)Zydus receives final approval from the USFDA for Apixaban Tablets, 2.5 mg and 5 mg and(2) Zydus receives final approval from the USFDA for Olmesartan Medoxomil andHydrochlorothiazide Tablets".